Breaking News

Financial Report: Johnson & Johnson 1Q

April 16, 2014

Revenues up 3% in the quarter

Johnson & Johnson

1Q Revenues: $18.1 billion (+4%)

1Q Earnings: $4.7 billion (+35%)

Comments: Worldwide pharmaceutical sales were $7.5 billion, up 11%, driven by STELARA, INVEGA, SUSTENNA/XEPLION, PREZISTA, and VELCADE, as well as new products OLYSIO/SOVRIAD, a combination treatment of chronic hepatitis C, and ZYTIGA for the treatment of prostate cancer. Results were negatively impacted by loss of exclusivity for ACIPHEX and CONCERTA. In the quarter, the FDA approved IMBRUVICA capsules for the treatment of chronic lymphocytic leukemia, and the European Commission granted conditional approval for SIRTURO as part of a combination regimen for pulmonary multi-drug resistant tuberculosis. R&D expenses were $1.8 billion, up 3%.

blog comments powered by Disqus
  • Single-Use Clarification System for High-Density Cell Cultures

    Single-Use Clarification System for High-Density Cell Cultures

    Tjebbe van der Meer, Sartorius Stedim Biotech||June 2, 2015
    Continuous improvements in growth media and cell line viability have resulted in increased biomass concentrations in biopharmaceutical production processes, making the downstream purification step more challenging. Body feed filtration has proven to be a successful method of solving similar issues in other industries. This robust technology is now available as a harvesting solution for biotechnology applications.

  • Newsmakers: John Chiminski

    Newsmakers: John Chiminski

    May 6, 2015
    Catalent Completes $52M Expansion at Winchester, KY, Facility

  • Will All Tablets and Capsules Have On-Dose Physical Chemical Identifiers Soon?

    Will All Tablets and Capsules Have On-Dose Physical Chemical Identifiers Soon?

    Kent Mansfield , president TruTag Technologies, Inc.||April 1, 2015
    As the global problem of counterfeit and diverted drugs continues to grow worldwide, will our medicine soon carry secure identifiers woven into the very fabric of the drug product? Advancing technology is finally allowing drug makers the ability to implement on-dose authentication.